HM43239 Demonstrates Durable Clinical Benefit in Acute Myeloid Leukemia

Dec 13, 2021 4:30pm EST

Aptose to Hold Corporate Update Monday, December 13th

Nov 29, 2021 7:30am EST

Aptose to Present at the Piper Sandler 33rd Annual Healthcare Conference

Nov 22, 2021 4:02pm EST

Aptose Reports Results for the Third Quarter 2021

Nov 11, 2021 4:01pm EST

Aptose Clinical Data to be Presented at the 2021 ASH Annual Meeting

Nov 04, 2021 9:00am EDT

Aptose Enters into Exclusive Worldwide License Agreement with Hanmi Pharmaceutical for Clinical-Stage Myeloid Kinome Inhibitor HM43239

Nov 04, 2021 6:00am EDT

Aptose to Report Third Quarter 2021 Financial Results and Hold Conference Call on Thursday, November 11, 2021

Oct 26, 2021 7:30am EDT

Aptose Expands Senior Leadership Team

Oct 25, 2021 8:00am EDT

Aptose to Present at September Investor Conferences

Aug 30, 2021 7:30am EDT

Aptose Reports Results for the Second Quarter 2021

Aug 03, 2021 4:01pm EDT